Zacks: Medgenics Inc (GNMX) Given Average Recommendation of “Hold” by Brokerages
Shares of Medgenics Inc (NASDAQ:GNMX) have been given a consensus broker rating score of 2.50 (Hold) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. Medgenics’ rating score has declined by 25% from 90 days ago as a result of various analysts’ ratings changes.
Analysts have set a 12 month consensus target price of $5.25 for the company and are expecting that the company will post ($0.17) EPS for the current quarter, according to Zacks. Zacks has also assigned Medgenics an industry rank of 191 out of 265 based on the ratings given to related companies.
Medgenics (NASDAQ:GNMX) traded up $0.01 during mid-day trading on Friday, hitting $2.24. The company had a trading volume of 85,314 shares, compared to its average volume of 392,522. The firm has a market cap of $132.90, a price-to-earnings ratio of -2.33 and a beta of 1.10. Medgenics has a 1-year low of $0.98 and a 1-year high of $6.18.
ILLEGAL ACTIVITY NOTICE: “Zacks: Medgenics Inc (GNMX) Given Average Recommendation of “Hold” by Brokerages” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/18/zacks-medgenics-inc-gnmx-given-average-recommendation-of-hold-by-brokerages.html.
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with MarketBeat.com's FREE daily email newsletter.